ESMO Breast 2024 | Role of endocrine therapy in early-stage HR-positive breast cancer

Simone Nardin, MD, Ospedale Policinico San Martino, Genoa, Italy, discusses the role of endocrine therapy in early-stage HR-positive breast cancer. Analyzing baseline characteristics of patients to predict outcomes and the efficacy of ovarian suppression helps refine follow-up and screening strategies. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.